In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leadership

Set Alert for Leadership

ImmunoGen’s Mark Enyedy On Striking Deals – And Curing Cancer

Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite – company shares are up nearly 200% this year. In this interview he discusses corporate restructuring, the evolving role of business development and making new scientific inroads against hard-to-treat cancers.

BioPharmaceutical Deals ImmunoOncology
Advertisement

Latest From Leadership

Zimmer Biomet Shows How To Keep Operational Issues From Eclipsing Strategic Goals

While Zimmer Biomet's search goes on for a new CEO to replace David Dvorak, who stood down in mid-summer, analysts are pressing for a replacement in short order to put stability back into the global No.2 orthopedic device group, which has sales headwinds and ongoing implant production issues at North Campus, Warsaw, to contend with.

Orthopedics Medical Device

Execs On The Move, November 2017

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

Execs On The Move, October 2017

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

BioPharmaceutical Medical Device

Execs On The Move, September 2017

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

BioPharmaceutical Medical Device

Halozyme’s “Hat Collector” Approach To Human Capital: Virtue in Versatility

A Q&A on biopharma workforce recruitment, training and C-suite oversight with Halozyme's Ken Schultz, MD. A supplement to our feature on the In Vivo/EBD Academy survey, "Future-Proofing Human Capital in the Global Life Sciences: Does Biopharma Have the Right Stuff?

BioPharmaceutical Leadership

Inside Bayer Oncology: An Interview With Robert LaCaze

Bayer AG may more often make headlines for its deal-making in consumer health and agriculture, but the massive German conglomerate sees oncology drugs as a key engine of future success within its high-growth pharmaceuticals business. A Q&A with Robert LaCaze, EVP of Bayer's new Oncology Strategic Business Unit.

Business Strategies Deals
See All
UsernamePublicRestriction

Register